<div id="readability-page-1"><p>Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given an average rating of &#34;Moderate Buy&#34; by the eight research firms that are  covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, two have given a buy rating and two have issued  a strong buy rating on  the company. The average 12-month price target among analysts that have covered the stock in the last year is $21.8333.</p><div><p><span></span><span>Get <strong>Theravance Biopharma</strong> alerts:</span></p></div><p>TBPH has been the topic of several analyst reports. Zacks Research raised shares of Theravance Biopharma from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, March 19th. B. Riley Financial upped their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, April 7th. TD Cowen upped their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a &#34;hold&#34; rating in a research report on Monday, March 23rd. Weiss Ratings lowered shares of Theravance Biopharma from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a research report on Friday, April 10th. Finally, Oppenheimer downgraded shares of Theravance Biopharma from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Thursday, March 5th.</p><p><b>Check Out Our Latest Report on TBPH</b></p><h2>Theravance Biopharma Trading Up 0.9%</h2><p>NASDAQ TBPH opened at $16.46 on Friday. The firm's fifty day moving average price is $16.14 and its two-hundred day moving average price is $17.20. Theravance Biopharma has a 1 year low of $8.33 and a 1 year high of $21.03. The firm has a market capitalization of $847.53 million, a P/E ratio of 8.11 and a beta of 0.17. </p><h2>Insider Activity at Theravance Biopharma</h2><p>In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders. </p><h2>Hedge Funds Weigh In On Theravance Biopharma</h2><p>Several institutional investors and hedge funds have recently modified their holdings of TBPH. AQR Capital Management LLC acquired a new position in shares of  Theravance Biopharma in the first quarter valued at about $101,000.  Jane Street Group LLC grew its stake in shares of  Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock valued at $1,258,000 after acquiring an additional 88,540 shares in the last quarter.  Creative Planning acquired a new stake in shares of  Theravance Biopharma in the second quarter valued at approximately $139,000.  American Century Companies Inc. raised its position in shares of  Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company's stock valued at $1,009,000 after buying an additional 5,794 shares in the last quarter.  Finally, Invesco Ltd. raised its position in shares of  Theravance Biopharma by 12.4% in the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company's stock valued at $279,000 after buying an additional 2,789 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Theravance Biopharma Company Profile</h2> (Get Free Report)<p>Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.</p><h2>Read More</h2><ul><li>Five stocks we like better than Theravance Biopharma</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Theravance Biopharma Right Now?</h2><p>Before you consider Theravance Biopharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.</p><p>While Theravance Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TBPH

<p>Theravance Biopharma, Inc. (NASDAQ:TBPH) has received a consensus rating of "Moderate Buy" from eight research firms. Analysts' ratings include four holds, two buys, and two strong buys, with an average 12-month price target of $21.83. Recent reports show varied ratings, with Zacks upgrading to strong buy and B. Riley Financial raising the price target to $17.00. The stock is currently trading at $16.46, with a market cap of $847.53 million. Institutional investors hold 99.10% of the stock, indicating strong interest in the company.</p>

Market Beat

Theravance BioPharma

Oppenheimer

Invesco

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages